Apiam Animal Health Limited (ASX:AHX) MD Dr. Chris Richards Speaks with ABN Newswire on Revenue Growth in the Business and the consolidation of acquisitions made by the company over the last two years.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to Jefferies Institutional Clients on 28 March 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce it has signed a Material Transfer Agreement with the globally-respected University of Oxford to acquire approximately 600 patient plasma samples for its endometriosis study.
Proteomics International Laboratories Ltd (ASX:PIQ) continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that is has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufacture of medical devices.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has been granted a patent in 19 major European countries for its platform technology to measure oxidative stress.
Apiam Animal Health Limited (ASX:AHX) today released its financial results for the six-months ended 31 December 2023 (H1 FY24).
